Skip to content

Ketamine: all studies

Page 99 of 448: studies 981 to 990 of 4,475, newest first. Back to the ketamine overview

Research

SLOW BUT STEADY: ORAL KETAMINE AS AN EFFECTIVE ADJUNCT IN DEPRESSION, ANXIETY AND PTSD

The International Journal of Neuropsychopharmacology February 12, 2025 *William Sulis

Abstract Intravenous and intranasal Ketamine have become important options for the rapid relief of symptoms in PTSD, Suicidality and in Treatment Resistant Depression and Anxiety. However, they are costly, require at least an out- patient clinic setting and have relatively short lived benefits. I present a pilot study examining 8 patients treated with oral Ketamine, 5 mg/kg for 12 treatments....

Is ketamine efficacious for rapid treatment of acute suicidal ideation in an emergency setting? Lessons learned from a pilot randomized controlled trial.

BMC research notes February 12, 2025 Maryam Barzkar, Kaveh Alavi, Kazem Malakouti et al. 1 citation

This study aimed to evaluate the efficacy of a single infusion of ketamine in inducing rapid remission of severe suicidal ideation, compared to Midazolam, in a population with acute suicidal thoughts. In a double-blind randomized controlled trial conducted in Tehran, Iran, from January to July 2022 (IRCT20220118053756N1), 36 inpatients with acute severe suicidal ideation were enrolled....

Ketamine Alters Tuning of Neural and Behavioral Spatial Working Memory Precision

bioRxiv Preprint Server February 10, 2025 Masih Rahmati, Flora Moujaes, Nina Purg Suljič et al. 1 citation preprint

Deficits in working memory (WM) are a hallmark of neuropsy-chiatric disorders such as schizophrenia, yet their neurobiological basis remains poorly understood. Glutamate N-methyl-D-aspartate receptors (NMDARs) are critical for spatial WM (sWM), with NMDAR antagonist ketamine known to attenuate task-evoked activation and reduce sWM accuracy. Cortical microcircuit models hypothesize that NMDAR...

DOI: 10.1101/2025.02.10.637233 (opens in new tab) Full text (opens in new tab) Memory deficits:memory problems Poorer memory Memory impairment Memory loss +12

Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial).

BMJ Open February 10, 2025 Kathryn Fletcher, Nadine Ezard, Krista J. Siefried et al. 1 citation

Methamphetamine use disorder is a significant public health concern. No pharmacological treatment options currently exist for methamphetamine use disorder, and psychotherapy is only moderately effective. Preliminary evidence suggests that ketamine-assisted psychotherapy produces sustained improvements in substance use and mental health symptomatology. In addition to direct antidepressant...

DOI: 10.1136/bmjopen-2024-092504 (opens in new tab) Full text (opens in new tab) Drug therapy Feasibility studies Psychosocial intervention Safety +6

Clinical trials since 2020 of rapid anti-suicidal ideation effects of ketamine and its enantiomers: a systematic review.

Translational Psychiatry February 6, 2025 Sumra Sajid, J John Mann, Michael F Grunebaum 3 citations

Suicide is a global public health problem with few empirically supported treatments. We conducted a systematic review of clinical trials (CT) since 2020 of racemic ketamine or one of its enantiomers' (R/S) potential to reduce suicidal ideation or behavior (SIB). An initial PubMed search on April 15th, 2024 yielded 2483 results. 104 relevant CTs were identified. An additional search using other...

DOI: 10.1038/s41398-025-03255-0 (opens in new tab) Full text (opens in new tab) Mental-health Suicide-prevention Ketamine-therapy Psychiatric-treatment +1

Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis.

BMC Pregnancy and Childbirth February 6, 2025 Moaz Yasser Darwish, Abdallah A Helal, Yousif Ahmed Othman et al. 8 citations

Postpartum depression (PPD) is categorized by the Disorders-Fifth Edition as depression that begins during pregnancy or within the first month after giving birth. Ketamine and esketamine have shown promising results in the treatment of several depressive disorders, which suggests that they may have a role in the prevention of PPD. This systematic review and meta-analysis aim to update evidence...

DOI: 10.1186/s12884-025-07186-y (opens in new tab) Full text (opens in new tab) Esketamine Mental health Postpartum depression ppd Antidepressants +2

Ketamine induces plasticity in a norepinephrine-astroglial circuit to promote behavioral perseverance.

Neuron February 5, 2025 Marc Duque, Alex B. Chen, Eric Hsu et al. 27 citations

Transient exposure to ketamine can trigger lasting changes in behavior and mood. We found that brief ketamine exposure causes long-term suppression of futility-induced passivity in larval zebrafish, reversing the "giving-up" response that normally occurs when swimming fails to cause forward movement. Whole-brain imaging revealed that ketamine hyperactivates the norepinephrine-astroglia circuit...

Sleep-administered ketamine/psychedelics: A streamlined strategy to address two challenges in research on ketamine and psychedelics.

European Psychiatry February 5, 2025 Shokouh Arjmand, Mats B Lindström, Carl M Sellgren et al. 1 citation

The dissociative effects of ketamine and psychedelics might be associated with their rapid antidepressant properties, raising questions about whether these effects are necessary for their therapeutic action. Additionally, the distinct dissociative experiences often reported by patients in clinical trials may reveal whether they receive an active treatment or a placebo, potentially introducing...

DOI: 10.1192/j.eurpsy.2025.14 (opens in new tab) Full text (opens in new tab) Ketamine Mechanism of action Rapid-acting antidepressants Psychedelics hallucinogens +6